Cargando…
Xanomeline-Trospium and Muscarinic Involvement in Schizophrenia
Schizophrenia is a severe mental illness that has its onset in late adolescence or early adulthood and is associated with significant dysfunction across multiple domains. The pathogenesis of schizophrenia remains unknown, but physiologic understanding of the illness has been driven by the dopamine h...
Autores principales: | Kidambi, Neil, Elsayed, Omar H, El-Mallakh, Rif S |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183173/ https://www.ncbi.nlm.nih.gov/pubmed/37193547 http://dx.doi.org/10.2147/NDT.S406371 |
Ejemplares similares
-
Evidence of trospium’s ability to mitigate cholinergic adverse events related to xanomeline: phase 1 study results
por: Breier, Alan, et al.
Publicado: (2023) -
Safety and tolerability of KarXT (xanomeline–trospium) in a phase 2, randomized, double-blind, placebo-controlled study in patients with schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022) -
Effectiveness of KarXT (xanomeline-trospium) for cognitive impairment in schizophrenia: post hoc analyses from a randomised, double-blind, placebo-controlled phase 2 study
por: Sauder, Colin, et al.
Publicado: (2022) -
Pharmacological Evaluation of the Long-Term Effects of Xanomeline on the M(1) Muscarinic Acetylcholine Receptor
por: Grant, Marianne K. O., et al.
Publicado: (2010) -
Transdermal Asenapine in Schizophrenia: A Systematic Review
por: Carrithers, Brennan, et al.
Publicado: (2020)